Additional Data From SEQUOIA-HCM Presented at HFSA Annual Scientific Meeting

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were presented virtually at the Heart Failure Society of America (HFSA) Annual Scientific Meeting by Martin Maron, M.D., Director of the Hypertrophic Cardiomyopathy Center at the Lahey Hospital and Medical Center.

The presentation was simultaneously published in the Journal of the American College of Cardiology¹.

In these responder analyses of data from SEQUOIA-HCM, key integrated clinical assessments, commonly relied upon by practicing cardiologists to inform treatment choice and response, were analyzed following 24 weeks of treatment with aficamten or placebo (in addition to standard of care in both cases) in the study population (n=282): 1) complete hemodynamic response (resting and Valsalva left ventricular outflow tract gradient [LVOT-G] <30 mmHg and <50 mmHg, respectively), 2) relief of symptoms (≥1 change in New York Heart Association [NYHA] Functional Class and/or ≥10-point increase in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score [KCCQ-CCS]), 3) enhanced exercise capacity (≥1.5 mL/kg/min change in peak oxygen uptake [pVO₂]), and 4) cardiac biomarker response (≥50% reduction in NT-proBNP).

Comparing patients treated with aficamten to placebo, 68% vs. 7% demonstrated a complete hemodynamic response, 71% vs 42% experienced relief of limiting symptoms, 46.5% vs 24% showed enhanced exercise capacity and 84% vs 8% demonstrated a substantial response in cardiac biomarkers (for all p<0.002 compared to placebo). Overall, 97% of patients treated with aficamten achieved one or more clinically relevant outcomes, 62% achieved at least three outcomes and 23% achieved all four outcomes. For each of the four outcomes assessed in these analyses, the number needed to treat (NNT) was fewer than 5 patients.

In a responder analysis of functional capacity (defined as pVO₂ ≥1.5 mL/kg/min and ≥1 improvement in NYHA class, or pVO₂ ≥3.0 mL/kg/min2 and no worsening in NYHA class), 42% of patients on aficamten and 14% of patients on placebo were responders, for a difference vs. placebo of 29% (95% CI: 18.8 - 38.6, p<0.001) and an NNT of 3. Additionally, among patients treated with aficamten who were eligible for septal reduction therapy at baseline (n=32), 88% were no longer eligible at 24 weeks (p=0.002 compared to placebo).

“In these prespecified analyses of SEQUOIA-HCM the addition of aficamten to standard of care was associated with important improvements in four key clinical markers used by cardiologists to inform HCM patient management strategies and prognosis. Included in these assessments are a complete hemodynamic response which was demonstrated in two-thirds of the patients in SEQUOIA-HCM,” said Stephen Heitner, M.D., Vice President, Head of Clinical Research. “These data elaborate on the primary results from SEQUOIA-HCM and further inform the relevance to clinical practice of aficamten as a next-in-class cardiac myosin inhibitor for adult patients with obstructive HCM.”

References:

1. Maron M, et al. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM. JACC. 2024.
2. CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575
3. Symphony Health 2016-2021 Patient Claims Data DoF;
4. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.
5. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.
6. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21